Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels.
about
Management of the Asthma-COPD Overlap Syndrome (ACOS): a Review of the Evidence.Severe asthma and asthma-COPD overlap: a double agent or identical twins?Anti-IgE therapy as novel target for asthma-COPD overlap syndrome: More questions before celebration.Type 2 immunity in asthma.Pharmacological mechanism of roflumilast in the treatment of asthma-COPD overlap
P2860
Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Omalizumab (anti-IgE) therapy ...... n circulating cytokine levels.
@en
type
label
Omalizumab (anti-IgE) therapy ...... n circulating cytokine levels.
@en
prefLabel
Omalizumab (anti-IgE) therapy ...... n circulating cytokine levels.
@en
P2860
P1476
Omalizumab (anti-IgE) therapy ...... n circulating cytokine levels.
@en
P2093
Ata Nevzat Yalcin
Betul Celik
P2860
P304
P356
10.3109/08923973.2016.1173057
P577
2016-04-28T00:00:00Z